Recs

0

Medical Device Makers Throwing Money Down the Tube

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Medical device companies may be the newest victim of Congress' power. And contrary to what you might think, that's probably a good thing.

I've written before that advertisements for medical devices such as Johnson & Johnson's (NYSE: JNJ  ) drug-eluting stent, Cypher, don't make a whole lot of sense. And nothing I've seen since has made me change my mind.

The Senate Aging Committee is currently investigating medical device companies' direct-to-consumer advertising campaigns. Unlike the ads from their pharmaceutical brethren, these ads don't have to equally weigh the benefits with the risks. Probably just as well. It'd be a real downer if they did because death is a potential risk of almost any surgery.

Even if the worst happens from the viewpoint of the companies -- a complete ban on advertisements -- I still don't think it would really have that big of an effect on medical device makers like Medtronic (NYSE: MDT  ) , Boston Scientific (NYSE: BSX  ) , or Abbott Labs (NYSE: ABT  ) .

In contrast, pharmaceutical companies should be very worried about increased clamoring to protect patients from the "vicious" heath-care companies. Pfizer (NYSE: PFE  ) , Eli Lilly (NYSE: LLY  ) , Merck (NYSE: MRK  ) , and the rest need the advertisements to get patients to talk to their doctors about their high cholesterol or erectile dysfunction. While they certainly boost sales, they also get patients talking to their doctors. And that's good.

However, medical device makers are in a business where the doctors are most likely to make the decision to use a particular device. I mean if you need a knee replaced or a stent put in, you're probably already talking to your doctor about various options.

Are patients really going to convince their doctors to cut them open just because they heard about a procedure on television? And even then, is the doctor more likely to use the device that patient heard about on television or the one the doctor is more comfortable using? The doctors are the ones who the medical device companies should focus their promotion dollars on, not the patients.

Smart investors should keep an eye out for advertisements and invest in companies that aren't throwing profits down the tube.

More Foolishness:

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Motley Fool CAPS is the place to go to post your agreement or disagreement to the above. Make an out- or underperform call on these companies; post a pitch about why and whether or not the ads are necessary. It's free. It's fun. And, it's Foolish.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer, Eli Lilly, and Johnson & Johnson are Motley Fool Income Investor picks. Pfizer is a Motley Fool Inside Value recommendation. Try any of our Foolish newsletters today, free for 30 days. The Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 18, 2008, at 4:44 PM, cutter66 wrote:

    I absolutely agree with your opinion. The bang-for-your-buck advertising for medical devices versus pharms isn't there.

    The most disturbing part of this is how docs make their decision about which device to use. There are those that are educated about their options and make their decision based on what product is best suited to the needs of the patient.

    On the flip side, your mother or grandmother might just get a device from the vendor whose sales rep is a fishing buddy with the doc or, worse yet, is involved in a psuedo-study that is designed to get easy money into the hands of the implanter. Quality and feature sets are ignored as is the best interests of the patient. Believe me, it happens this way all to frequently.

    If a loved one is in need of a medical device and time allows, do the research and ask a boatload of questions. Any doc that says they are all the same might just be the second one I described above.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 731278, ~/Articles/ArticleHandler.aspx, 5/25/2012 4:26:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:02 PM
MDT $36.88 Down -0.19 -0.51%
Medtronic, Inc. CAPS Rating: *****
MRK $37.55 Down -0.05 -0.13%
Merck & Co., Inc. CAPS Rating: ****
PFE $22.13 Down -0.01 -0.05%
Pfizer, Inc. CAPS Rating: ****
LLY $41.11 Down -0.05 -0.12%
Eli Lilly & Co. CAPS Rating: ****
ABT $62.25 Down -0.17 -0.27%
Abbott Laboratorie… CAPS Rating: *****
BSX $5.87 Down -0.04 -0.68%
Boston Scientific… CAPS Rating: ***
JNJ $62.51 Down -0.59 -0.94%
Johnson & Johnson CAPS Rating: *****

Advertisement